Targeting Solid Tumors with Combination Therapies using an Engineered Nanoparticle Solution

 

Cytimmune recently sold its technology to Zahav Bioscience LLC. This web site will be updated soon to reflect this change.

Cytimmune is a phase II ready biotechnology company leading the development of next-generation nanotechnology-based cancer therapies that are capable of delivering complex biologic and enhanced small molecule drugs.

Our IO+ platform enables simultaneous destruction of tumor support structures, killing of cancer cells, and activation of an anti-cancer immune response.

2022.png

Leadership Team

Cytimmune has recently transitioned to new corporate and scientific leadership, and we are poised to rapidly advance the company's research and clinical priorities in 2022 and beyond. Meet the team.

fully loaded particle square.png

IO+ Technology

This phase 2 ready, virus-sized, engineered vector attacks solid tumors using multiple mechanisms of action. IO+ can deliver immune stimulating therapies in combination with small molecule & complex biologics. Learn more about the IO+ platform.

pipeline small.jpg

Pipeline

Using our IO+ platform technologies, we are developing combination cancer treatments that activate anti-cancer immune responses, deliver enhanced small molecule drugs, and improve the performance of targeted precision medicines. Explore our pipeline.

Recent Company Updates

Featured
NCL signs MTA with Cytimmune Sciences for novel nanomedicine
NCL signs MTA with Cytimmune Sciences for novel nanomedicine

Cytimmune and the U.S. Nanotechnology Characterization Laboratory (NCL) have signed a Material Transfer Agreement (MTA). The focus of this agreement is a new nanomedicine construct developed by Cytimmune that simultaneously delivers Interferon gamma (IFN-y) and Tumor Necrosis Factor alpha (TNF alpha) on the same gold nanoparticle. Cytimmune will supply newly formulated therapeutic to the NCL for in vitro studies and characterization. Studies are expected to be initiated in 2021.

Tokyo University of Science Signs Research Agreement with Cytimmune Sciences to Investigate IO+ nanomedicines in combination with checkpoint inhibitors.
Tokyo University of Science Signs Research Agreement with Cytimmune Sciences to Investigate IO+ nanomedicines in combination with checkpoint inhibitors.

CytImmune has signed an agreement with the Tokyo University of Science, Division of Molecular Regulation of Inflammation and Immune diseases to investigate and confirm synergies between TNF alpha and existing immunotherapies.

NCI to Conduct Phase 2 Studies of Cytimmune’s lead nanomedicine, CYT-6091
NCI to Conduct Phase 2 Studies of Cytimmune’s lead nanomedicine, CYT-6091

CytImmune has signed a Clinical Trial Agreement with the National Cancer Institute to conduct clinical studies to include a Phase 2 trial of CytImmune’s lead therapeutic construct, CYT-6091.

Clinical studies will be conducted by Dr. Naris Nilubol, an oncologist and surgeon leading the NCI’s endocrine oncology branch.

From The Lab - Breaking Open a Tumor in 90 minutes.

CYT-6091, an IO+ therapeutic that delivers high-dose TNF alpha, has demonstrated the ability to radically alter the tumor microenvironment (TME). One of the many anti-tumor activities of TNF alpha is to rapidly destroy tumor blood vessel networks.

CYT-6091 was injected into mice with solid tumors. We then injected a tracking molecule (bright green) that would enable us to see where CYT-6091 was destroying blood vessels.

As shown in the video, the tracking molecule stays inside of normal healthy tissues even after administration of CYT-6091. Within one hour, tumor vessels are destroyed by CYT-6091 releasing the tracking dye.

This shows the highly targeted nature of Cytimmune’s IO+ platform and demonstrates one aspect of the potential clinical value of high-dose TNF alpha.